Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome
Stopped due to the decision of company Top management
Conditions
- Schnitzler Syndrome
- Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder)
Interventions
- BIOLOGICAL: 80 mg RPH-104
- DRUG: Placebo
Sponsor
R-Pharm Overseas, Inc.
Collaborators